What is ADC Therapeutics's latest dividend and current dividend yield?

What is the market's earnings forecast for ADC Therapeutics next quarter?

What factors drove the changes in ADC Therapeutics's revenue and profit?

What is ADC Therapeutics's gross profit margin?

Did ADC Therapeutics beat or miss consensus estimates last quarter?

What guidance did ADC Therapeutics's management provide for the next earnings period?

What were the key takeaways from ADC Therapeutics’s earnings call?

What were the key takeaways from ADC Therapeutics's earnings call?

- **Strategic Focus on ZYNLONTA**: 50% cost reduction and clinical trial progress (LOTIS-5, LOTIS-7) position ZYNLONTA for $600M-$1B peak U.S. revenue.
- **Q4 2025 Financials**: $22.3M net product revenue, $261M cash runway, and 15% Y/Y operating expense reduction.
- **Key Catalysts**: Q2 2026 LOTIS-5 PFS readout, Q4 2026 LOTIS-7 data, and 2027 regulatory filings for second-line DLBCL expansion.
- **Market Potential**: 10% third-line DLBCL share ($100M) + second-line expansion ($200M-$300M) drive long-term growth.

**【CEO Summary Section】**
- **Strategic Focus on ZYNLONTA**: CEO Ameet Mallik emphasized the company's focus on optimizing ZYNLONTA's lifecycle, reducing operating costs by 50%, and advancing clinical trials (LOTIS-5 and LOTIS-7). The goal is to establish ZYNLONTA as a backbone therapy in DLBCL and expand into indolent lymphomas.
- **Revenue Performance**: 2025 net product revenues were $73.6 million, stable year-over-year, with Q4 revenue of $22.3 million driven by new account activations. ZYNLONTA maintains a 10% share in the third-line DLBCL setting.
- **Clinical Milestones**: LOTIS-5 (ZYNLONTA + rituximab) Phase III trial targeting second-line DLBCL is expected to report top-line PFS data in Q2 2026. LOTIS-7 (ZYNLONTA + glofitamab) showed 90% ORR and 78% CR in 49 evaluable patients, positioning it as a potential best-in-class bispecific combination.
- **Revenue Potential**: CEO outlined a $600 million to $1 billion U.S. peak revenue target for ZYNLONTA, assuming compendia inclusion and regulatory approvals. LOTIS-5 alone could add $200 million to $300 million in peak sales.

**【CFO Financial Commentary】**
- **Financial Results**: Q4 2025 net product revenues were $22.3 million (vs. $17.4 million in Q4 2024). Full-year 2025 net product revenues were $73.6 million (vs. $69.3 million in 2024). GAAP net loss was $6.4 million for Q4 2025, improving from $30.7 million in Q4 2024 due to reduced R&D expenses and a deferred royalty adjustment.
- **Cost Efficiency**: Total adjusted operating expenses decreased 15% Q/Q and 6% Y/Y, driven by R&D expense reductions. Full-year 2025 cash balance was $261 million, providing a runway into 2028.
- **Future Catalysts**: CFO highlighted 2026 data readouts for LOTIS-5 (Q2), LOTIS-7 (Q4), and indolent lymphoma IITs (2026-2027). Regulatory filings for LOTIS-5 are expected in H2 2026, with potential approvals in 2027.

**【Q&A Highlights】**
- **LOTIS-5 Timing and Data**: CEO confirmed Q2 2026 top-line PFS readout, with full results published by year-end. Secondary endpoints and safety data will be shared, but CR durability will likely await later publications.
- **Market Share and Upside**: CEO noted ZYNLONTA's 10% share in third-line DLBCL and potential to maintain this in second-line. LOTIS-5's CR rate could drive share expansion, with upside if clinical profile exceeds expectations.
- **Capital Allocation**: CFO stated R&D expenses will decline in 2026-2027 as trials wind down. Commercial investment will focus on ZYNLONTA's second-line launch, with incremental field force and MSL expansions.
- **OS Considerations**: CEO acknowledged OS as a potential differentiator but emphasized PFS as the primary endpoint for LOTIS-5. Subsequent therapies (e.g., bispecifics) may impact OS but are outside trial control.


ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript

- **Stable ZYNLONTA revenue**: $15.8M Q3 2025, maintaining third-line DLBCL market position.
- **Pipeline momentum**: LOTIS-5 Phase III data H1 2026, LOTIS-7 interim update Q4 2025 with 93.3% ORR.
- **Peak revenue vision**: $600-1B U.S. for ZYNLONTA, driven by second-line DLBCL ($200-300M) and MZL ($100-200M).
- **Financial strength**: $292M cash post-PIPE, 2028+ runway, 12% YoY expense reduction.

**【CEO Summary Section】**
- Q3 2025 net product revenues: $15.8 million (down 12.2% YoY), reflecting stable demand for ZYNLONTA in third-line DLBCL.
- Key pipeline updates:
  - LOTIS-5 Phase III: Top-line data expected H1 2026; targeting $200-300M peak revenue in second-line DLBCL.
  - LOTIS-7 Phase Ib: 93.3% ORR, 86.7% CR in 30 evaluable pts; interim update with 6+ months follow-up planned Q4 2025.
- Peak revenue potential: $600-1B in U.S. for ZYNLONTA across DLBCL and indolent lymphomas.
- $60M private placement extends cash runway to 2028.

**【CFO Financial Commentary】**
- Q3 2025 financials:
  - GAAP net loss: $41M (vs. $44M YoY)
  - Non-GAAP operating expenses: $45M (12.1% YoY decline)
  - Cash balance: $234.7M (pre PIPE) → $292.3M post $60M financing.
- R&D efficiency: $15M reduction in expenses vs. 2024.
- Upcoming catalysts: LOTIS-5 data H1 2026, LOTIS-7 regulatory engagement 2026.

**【Q&A Highlights】**
- LOTIS-7 enrollment: Accelerated post-June data; targeting 100 pts but may complete sooner.
- Revenue ramp timing: Regulatory approvals/compendia listings expected H1 2027, with 2-year ramp-up.
- Frontline DLBCL strategy: Monitoring bispecifics; no plans for standalone Phase III.
- Sales force strategy: Balanced approach for complex (academic) vs. broad-access (community) settings.
- Indolent lymphoma potential: MZL ($100-200M peak) > FL due to lower competition and higher CR rates (70% vs. 30%).

ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 net product revenues up 6% YoY to $18.1 million, with first-half 2025 up 1.7% to $35.5 million.
- **Clinical Success**: ZYNLONTA + glofitamab achieves 86.7% CR in DLBCL (vs. 47-62% in bispecific trials); ZYNLONTA + rituximab Phase III on track for 2026 BLA.
- **Financial Strength**: $264.6M cash runway extended to 2028; $100M private placement offsets $13.1M restructuring costs.
- **Strategic Focus**: $600M-$1B peak sales target for ZYNLONTA across DLBCL and indolent lymphomas; PSMA ADC IND by end-2025.

**【CEO Summary Section】**
- Q2 2025 net product revenues: $18.1 million (Q2 2024: $17 million), first-half 2025: $35.5 million (2024: $34.9 million). 
- Promising LOTIS-7 data: ZYNLONTA + glofitamab achieved 93.3% ORR, 86.7% CR in 30 evaluable DLBCL patients. Expansion to 100 patients at 150 μg/kg dose underway.
- LOTIS-5 Phase III confirmatory trial on track to reach PFS events by end-2025. ZYNLONTA + rituximab combo targeting second-line DLBCL.
- Marginal zone lymphoma (MZL) Phase II IIT: 85% ORR, 69% CR, safety consistent with ZYNLONTA profile.
- Strategic focus: ZYNLONTA commercialization, PSMA ADC development. U.K. facility closure reduces workforce by ~30%, extending cash runway to 2028.
- Peak revenue potential: $600M-$1B in U.S. for ZYNLONTA across DLBCL and indolent lymphomas.

**【CFO Financial Commentary】**
- Q2 2025 GAAP net loss: $56.6 million ($0.50/share) vs. $36.5 million ($0.38/share) in 2024. Non-GAAP operating expenses: $47.8 million (8% YoY increase).
- Restructuring costs: $13.1 million (Q2 2025) including $6.7M severance and $6.4M U.K. facility impairment.
- Cash position: $264.6 million as of June 2025 (vs. $194.7 million March 2025), driven by $100M private placement.
- Key catalysts: LOTIS-5 PFS data (end-2025), LOTIS-7 enrollment completion (mid-2026), PSMA ADC IND (end-2025).

**【Q&A Key Highlights】**
- **Roche CRL Impact**: Unmet need persists in second-line DLBCL; LOTIS-5 design (120-patient randomized, 90% power) and safety profile (80% ORR, 50% CR) differentiate from competitors.
- **LOTIS-7 Durability**: 25/26 CR patients maintained response >12 months; no additive toxicity vs. monotherapies. FDA discussions拟于2025年下半年启动。
- **Indolent Lymphoma Strategy**: MZL IIT预计2025年完成50患者入组，40%+ CR率目标；单药ZYNLONTA安全性适合长期治疗。
- **Commercialization**: 90% DLBCL目标市场覆盖，MSL团队覆盖学术/社区中心；LOTIS-7数据将通过医学会议而非销售推广传播。

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

- **ZYNLONTA Combination Breakthrough**: 90.9% complete response rate in LOTIS-7 trial with ZYNLONTA + glofitamab, positioning as potential best-in-class bispecific combo.
- **Sustained Revenue Performance**: Q1 2025 net product revenue of $17.4 million aligns with prior year, reflecting stable commercial execution.
- **Key 2025 Catalysts**: LOTIS-7 data readout at EHA (June), LOTIS-5 PFS events by year-end, and $194.7M cash runway to H2 2026.
- **Strategic Focus**: Shifting resources to high-priority ADC programs (PSMA, Claudin-6) following ADCT602 discontinuation.

**【CEO Summary Section】**
- Q1 2025 total revenue reached $23 million, including $17.4 million in net product revenue for ZYNLONTA, consistent with Q1 2024 levels.
- ZYNLONTA + glofitamab combination (LOTIS-7) showed 95.5% overall response rate (ORR) and 90.9% complete response rate (CR) in 22 evaluable patients, with no new safety signals observed.
- Expanded enrollment to 100 patients in LOTIS-7 is being considered to support regulatory and compendia strategies, with updated data expected at EHA (June 2025).
- LOTIS-5 Phase 3 trial targeting second-line DLBCL patients remains on track to reach pre-specified PFS events by end-2025, with top-line results expected late 2025/early 2026.
- Cash runway extended into H2 2026, supporting ongoing clinical development and commercial expansion.

**【CFO Financial Commentary】**
- Q1 2025 GAAP net loss of $38.6 million (-17% YoY) driven by $5 million milestone payment from Health Canada approval and 5% reduction in non-GAAP operating expenses.
- Cash balance of $194.7 million as of March 31, 2025, reflecting net loss and timing of cash receipts/payments.
- Key 2025 financial priorities: managing cash burn while advancing high-value clinical programs (LOTIS-5, LOTIS-7, MZL IIT).

**【Q&A Highlights】**
- LOTIS-7: 40 patients enrolled in dose expansion arm as of Q1, with additional patients to be presented at EHA/ICML. CR durability >12 months observed in early data.
- Regulatory Strategy: Planning meetings with regulators in H2 2025 to discuss potential paths for ZYNLONTA + glofitamab combination.
- ADCT602 Discontinuation: Minimal financial impact, freeing resources to focus on core ADC pipeline (PSMA/ Claudin-6 exatecan-based ADCs).
- LOTIS-5: Safety run-in data shows 50% CR rate and 8.3-month PFS, with full trial powered to demonstrate superiority vs. standard therapy.

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

- **Operational Strength**: 13% opex reduction and $251M cash runway support aggressive ZYNLONTA expansion.
- **Clinical Excellence**: LOTIS-5 (80% ORR) and LOTIS-7 (94% ORR) combo data position ZYNLONTA as second-line DLBCL leader.
- **Growth Catalysts**: $600M-$1B peak US revenue target via second-line approvals and indolent lymphoma expansion.
- **Pipeline Differentiation**: Claudin-6 ADC outperforms DXd with superior potency and no ILD, poised for 2025 data readouts.

**【CEO Summary Section】**
- **2024 Key Achievements**: Maintained ZYNLONTA revenue at $69.3M despite bispecific competition, reduced operating expenses by 13% YoY, and strengthened balance sheet with $251M cash runway to H2 2026.
- **ZYNLONTA Expansion**: Phase 3 LOTIS-5 trial for second-line DLBCL shows 80% ORR and 50% CR in safety lead-in; Phase 1b LOTIS-7 combo with glofitamab achieves 94% ORR and 72% CR in relapsed/refractory DLBCL.
- **Peak Revenue Potential**: $600M-$1B in US for ZYNLONTA across DLBCL and indolent lymphomas, driven by second-line combo approvals and compendia listings.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Net product revenue $16.4M (flat vs. Q4 2023), GAAP net loss $30.7M (-64% YoY). Full year 2024 non-GAAP operating expenses down 13% to $111.4M.
- **Cash Position**: $251M as of Dec 31, 2024, supporting operations into H2 2026. Non-GAAP adjusted net loss $26.5M for Q4, improving 67% YoY.

**【Q&A Highlights】**
- **Competitor Impact**: ADCETRIS + R2 approval expected to have limited impact, with 50% of second-line DLBCL patients not suitable for bispecifics.
- **Solid Tumor Pipeline**: Claudin-6 ADC shows >10 therapeutic index vs. DXd, with AACR presentation revealing ILD-free profile.
- **Regulatory Strategy**: Planning 2025 regulatory discussions for LOTIS-7 and compendia listings post 100-patient data publication.

ADC Therapeutics (ADCT)-27 Mar 25-2024 Q4 Earnings call transcript

ADC Therapeutics (ADCT)-7 Nov 24-2024 Q3 Earnings call transcript

Adc Therapeutics (ADCT)-6 Aug 24-2024 Q2 Earnings call transcript

Adc Therapeutics (ADCT)-6 May 24-2024 Q1 Earnings call transcript

Adc Therapeutics (ADCT)-13 Mar 24-2023 Q4 Earnings call transcript

- **ZYNLONTA sales decline**: Q3 2023 net sales $14.3M (-33% YoY) due to restructuring, competition, and gross-to-net pressures.
- **Commercial pivot success**: Field force fully ramped up, call volumes rebounding, community oncologist engagement prioritized.
- **Pipeline momentum**: 
  - ZYNLONTA combination trials (LOTIS-5, LOTIS-7) progressing; ASH 2023 follicular lymphoma data shows 95% ORR
  - ADC pipeline (ADCT-601, ADCT-901, ADCT-602) expected to release H1 2024 data
- **Financial discipline**: 23% YoY operating expense reduction, cash runway to mid-2025.

**【CEO Opening Remarks】**
- Q3 2023 ZYNLONTA net sales: $14.3 million (-33% YoY), driven by field force restructuring, competition (bispecifics), and higher gross-to-net deductions.
- Restructured commercial model focused on community oncologists, with field force now fully ramped up post-disruption.
- Clinical pipeline updates: 
  - LOTIS-5 Phase 3 trial (ZYNLONTA + rituximab in DLBCL) shows 80% ORR, 0% CR, 8-month median DoR; Mitsubishi Tanabe joins for Japan regulatory compliance.
  - LOTIS-7 Phase 2 trial (ZYNLONTA + bispecifics) enrolling across DLBCL, follicular, and marginal zone lymphoma.
  - ADCT-601 (AXL-targeted ADC), ADCT-901 (KAAG1-targeted ADC), and ADCT-602 (CD22-targeted ADC) in Phase 1 trials with initial data expected H1 2024.
- Operating expenses down 23% YoY, cash runway extended to mid-2025.

**【CCO Commercial Update】**
- Q3 sales decline due to: 
  - 3-month field force restructuring (half team new/reassigned roles)
  - Competitive dynamics (bispecifics, CAR-T adoption)
  - Medicare Part B discarded drug policy impact
- Community oncologist engagement key to recovery: 
  - Call volumes rebounded to pre-restructure levels in August/September (+40% vs prior 4 months)
  - ZYNLONTA positioned as monotherapy with manageable safety profile for outpatient use
- Academic vs. community split: 
  - Bispecifics dominate academic centers (complex therapy access)
  - Community treaters prefer ZYNLONTA for relapsed/refractory DLBCL

**【CMO Pipeline Update】**
- ZYNLONTA combination trials: 
  - LOTIS-5: 350-patient Phase 3 trial targeting second-line DLBCL; safety run-in data shared at SOHO
  - LOTIS-7: ZYNLONTA + bispecifics trial shows strong interest from investigators
  - ASH 2023 abstract: ZYNLONTA + rituximab in follicular lymphoma shows 95% ORR, 86% CR
- ADC pipeline: 
  - ADCT-601 (AXL) dose escalation ongoing in NSCLC/sarcoma; pancreatic cancer cohort added
  - ADCT-901 (KAAG1) dose escalation in solid tumors
  - ADCT-602 (CD22) expanding clinical trial sites for ALL

**【CFO Financial Update】**
- Q3 2023 financials: 
  - Cash balance: $310 million (down $37 million QoQ)
  - Non-IFRS operating expenses: $42.3 million (-23% YoY)
  - IFRS net loss: $47.8 million
- 2024 outlook: 
  - Maintain operating expenses below 2022 levels
  - Key catalysts: H1 2024 ADC pipeline data, LOTIS-5 enrollment completion, partnership exploration

Actual	-2.01	-0.58	-0.82	-0.67	-0.95	-0.93	-0.45	-0.22	-0.84	-0.65	-0.3	-0.74	-0.58	-0.58	-1.03	-0.56	-0.38	-0.42	-0.29	-0.36	-0.5	-0.3	-0.04
Forecast	-0.65	-0.77	-0.494	-0.905	-0.86	-0.9171	-0.8457	-0.6733	-0.7983	-0.3529	-0.4833	-0.02	-0.6996	-0.634	-0.5021	-0.5558	-0.4572	-0.395	-0.4117	-0.4033	-0.492	-0.3633	-0.2683
Surprise	-209.23%	+24.68%	-65.99%	+25.97%	-10.47%	-1.41%	+46.79%	+67.33%	-5.22%	-84.19%	+37.93%	-3600.00%	+17.10%	+8.52%	-105.14%	-0.76%	+16.89%	-6.33%	+29.56%	+10.74%	-1.63%	+17.42%	+85.09%

ADCT

ADCT fundamentals

ADCT Q4 2025 Earnings

Earnings Call

You can ask Aime

ADCT

ADCT fundamentals

ADCT Q4 2025 Earnings

Earnings Call

ADCT Earnings Call Summary for Q4/20258:30 AM on Mar 10, 2026

ADCT Earnings Call Summary for Q3/20258:30 AM on Nov 10, 2025

ADCT Earnings Call Summary for Q2/20258:30 AM on Aug 12, 2025

ADCT Earnings Call Summary for Q1/20258:30 AM on May 14, 2025

ADCT Earnings Call Summary for Q4/20248:30 AM on Mar 27, 2025

You can ask Aime